H.R. 8840

Fair Care Act of 2026

Sponsor: Bruce Westerman · 0 cosponsors

Follow this bill

Official summary

No official summary yet.

Text of the bill

Expand all

I Modernization of health savings accounts

A Modernization of health savings accounts and contributions

B Assistance to health savings accounts

II Improving Private Health Insurance

A Maintaining Protections for Patients with Preexisting Conditions

B Expanding Coverage Options

C Improving Commercial Health Insurance

III Competition, Transparency and Accountability

A Provider and Insurer Competition

B Price Transparency

C Prescription Drug Competition and Innovation

Sec. 348. Exclusivity period for brand name biological products

(a) In general. Section 351(k)(7)(A) of the Public Health Service Act (42 U.S.C. 262(k)(7)(A)) is amended by striking 12 years and inserting 5 years.

(b) Conforming changes. Paragraphs (2)(A) and (3)(A) of section 351(m) of the Public Health Service Act (42 U.S.C. 262(m)) is amended by striking 12 years each place it appears and inserting 5 years.

(c) Applicability. This section and the amendments made by this section apply only with respect to a biological product for which the reference product (as such term is used in section 351 of the Public Health Service Act (42 U.S.C. 262)) is licensed under subsection (a) of such section on or after the date of enactment of this Act.

D Prescription Drug and Pharmacy Benefit Manager Transparency

E Medicare and Medicaid Prescription Drug Reforms

F Medical Malpractice Reform

IV Medicare and Medicaid Reforms

A Medicaid Reforms

B Medicare Reforms

C Medicare Choice and Competition

D Telehealth Improvements and Expansion